Experimental drug shows promise in liver cancer fight
NCT ID NCT04358185
First seen May 13, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first treatment. The drug works by blocking a protein that helps cancer spread. The main goals were to check safety and see if tumors shrank. Results help guide future research, but the drug is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.